The company is developing a drug to treat traumatic brain injury using a molecule extracted from marine macroalgae. This molecule targets the immune system to promote repair after brain trauma. The therapy aims to reduce stimulate the immune cells and enhance neurological recovery. We also work to valorise extraction by-products, ensuring a sustainable, biotech-driven approach to neurorepair. Expertise is sought in polysaccharide chemistry and extraction of molecules at pharmaceutical grade.
Ref. BOFR20260318036 Empresa francesa que ofrece una alternativa 100% reciclada al hormigón y la piedra busca socios comerciales.
A young French industrial company, founded in 2021, develops and commercializes an innovative construction material made entirely from recycled inputs. Designed to replace concrete and natural stone in outdoor developments, the material supports a fully...
Abr 27, 2026
















